Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04369053 · ClinicalTrials.gov registry record
Prevention of Colorectal Cancer Through Multiomics Blood Testing
A clinical trial, sponsored by Freenome Holdings.
- Completed
- Registry status
- 48,995
- Enrollment target
NCT04369053: Completed study, sponsored by Freenome Holdings.
NCT04369053 is a clinical trial that has completed, run by Freenome Holdings. The registered enrollment target is 48,995 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04369053 has completed, sponsored by Freenome Holdings.
- COMPLETED
- Registry status
- 48,995 participants
- Enrollment target
Study Summary
The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.
Primary Outcome
Proportion of participants with a positive test result among those who had a diagnosis of colorectal cancer
Interventions
- DIAGNOSTIC_TEST Freenome test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48,995 participants |
| Start Date | 2020-05-20 |
| Est. Completion | 2024-02-29 |
What the finished NCT04369053 record still lists
NCT04369053 is an observational study that tracks outcomes without assigning an intervention. Its 48,995 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Freenome test is the first listed.
NCT04369053 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04369053 about?
NCT04369053 is a clinical study titled "Prevention of Colorectal Cancer Through Multiomics Blood Testing". The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.
What is the current status of trial NCT04369053?
This trial is currently completed. The enrollment target is 48,995 participants. The study started on 2020-05-20. Estimated completion is 2024-02-29.
What interventions are being tested in trial NCT04369053?
The interventions under investigation include: Freenome test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04369053?
This trial is sponsored by Freenome Holdings, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06655974 · 48,000 participants · NA
Predictive Modeling for Social Needs in Emergency Department Settings
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- NCT03452774 · 50,000 participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI